One-Liner
A predictive score estimating the probability FDA will issue a National Priority Voucher for a given drug indication, for use by regulatory affairs directors and biotech hedge funds.
AI Thinking Process
FDA National Priority Voucher programme (Q1 2026) speeds reviews for selected sponsors. Non-voucher sponsors wait longer; PDUFA delay costs $3-15M/month for small biotechs. Regulatory affairs directors monitor FDA dockets manually with no data-driven probability estimate.
G008 frequency trap: a biotech needs this once per drug programme over multi-year periods. Per-use purchase ~$50-200K consulting equivalent. Weak subscription frequency (G064: one-time regulatory event = consulting not SaaS).
G085: biotech hedge funds (Baker Brothers, RA Capital, Avoro) track voucher-implications across 30-50 portfolio programmes. Each voucher call moves security price. Probability index as alt-data feed: $100K/year × 30 funds = $3M ARR. Plausible.
EvaluatePharma, GlobalData, Informa Citeline Pharma Intelligence run FDA signal feeds. Voucher-probability index is their adjacency — would add as feature within 6-12 months (G006). Moat only through primary-source data (advisory transcript NLP, ex-FDA panels).
45% conviction — below 50% painpoint threshold. TAM too small ($8M ARR ceiling with ~40 customers), feature-absorbable by Informa/GlobalData within 12 months. The voucher theme needs to be a feature inside Evaluate/GlobalData, not an independent product.
No third pivot available — upstream buyer is the biotech itself (reverts to G064 consulting engagement). TAM bound is structural not positional. Resurrection FAILED.
Kill Reason
Per-drug, per-submission event means this is consulting not SaaS (G064). Pivot to biotech hedge-fund alt-data subscription failed on TAM ceiling: approximately 40 biotech funds × $200K/year = $8M ARR ceiling. Informa/GlobalData could absorb this as a 6-12 month feature addition, and they have existing relationships with every likely customer.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Open-source middleware (HAMi) already provides heterogeneous AI computing virtualization for free. Proprietary play is squeezed between free open-source and vertically integrated hardware vendor ecosystem.
killed: 5+ funded competitors including Cast AI ($1B valuation), OneChronos (backed by Nobel laureate), Akash Network (decentralized, 80% cheaper), Argentum AI (blockchain-settled). Market is claimed with massive capital.
killed: Template epidemic (G003) + industry-pain-form death pattern (G005) fire simultaneously. 13+ existing compliance tools. A prompt could do 80% of this.